TREM-话题@MedSci

#TREM#

40篇内容 | 1294人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1796399, encodeId=5ac51e963991d, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, objectType=article, longId=219629, objectId=09d321962921, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09d321962921, replyNumber=0, likeNumber=91, createdTime=2022-05-05, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09d321962921, moduleTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09d321962921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796403, encodeId=66fb1e96403b6, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=NEJM Evid：Tremelimumab联合Durvalumab用于不可切除肝细胞癌的治疗, objectType=article, longId=729494, objectId=1842e294948c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1842e294948c, replyNumber=0, likeNumber=102, createdTime=2022-11-04, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1842e294948c, moduleTitle=NEJM Evid：Tremelimumab联合Durvalumab用于不可切除肝细胞癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1842e294948c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796398, encodeId=396a1e96398ae, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率, objectType=article, longId=218686, objectId=4c14218686ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c14218686ce, replyNumber=0, likeNumber=112, createdTime=2022-09-16, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c14218686ce, moduleTitle=Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c14218686ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796402, encodeId=68741e96402ca, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Lancet Neurol：可溶性TREM2与常染色体显性遗传阿尔茨海默病其他标志物及认知功能的相关性, objectType=article, longId=301291, objectId=5d4330129115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d4330129115, replyNumber=0, likeNumber=126, createdTime=2022-06-28, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d4330129115, moduleTitle=Lancet Neurol：可溶性TREM2与常染色体显性遗传阿尔茨海默病其他标志物及认知功能的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d4330129115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796401, encodeId=a85d1e96401c6, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处, objectType=article, longId=294612, objectId=c7ac294612ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7ac294612ce, replyNumber=0, likeNumber=137, createdTime=2022-12-02, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7ac294612ce, moduleTitle=Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7ac294612ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796400, encodeId=19cc1e964006b, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, objectType=article, longId=220795, objectId=abf7220e9596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abf7220e9596, replyNumber=0, likeNumber=67, createdTime=2022-04-11, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abf7220e9596, moduleTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abf7220e9596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796397, encodeId=3c561e963979e, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究, objectType=article, longId=214768, objectId=1da3214e68e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da3214e68e5, replyNumber=0, likeNumber=89, createdTime=2021-09-27, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da3214e68e5, moduleTitle=J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da3214e68e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796394, encodeId=e3bb1e96394b1, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=欧盟委员会批准了TREMFYA®（guselkumab）治疗活动性银屑病关节炎（PsA）, objectType=article, longId=203779, objectId=0bb5203e7985, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bb5203e7985, replyNumber=0, likeNumber=131, createdTime=2021-03-23, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bb5203e7985, moduleTitle=欧盟委员会批准了TREMFYA®（guselkumab）治疗活动性银屑病关节炎（PsA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bb5203e7985)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796393, encodeId=0bc01e9639352, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=TREMFYA（guselkumab）治疗成人银屑病关节炎：显著减少了疲劳症状, objectType=article, longId=203134, objectId=b12e2031349b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12e2031349b, replyNumber=0, likeNumber=80, createdTime=2021-07-28, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12e2031349b, moduleTitle=TREMFYA（guselkumab）治疗成人银屑病关节炎：显著减少了疲劳症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b12e2031349b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796391, encodeId=d6f71e9639158, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率, objectType=article, longId=202204, objectId=7085202204a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7085202204a8, replyNumber=0, likeNumber=97, createdTime=2021-01-04, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7085202204a8, moduleTitle=III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7085202204a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796396, encodeId=5d9f1e963961f, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Acta Neuropathologica: 朊病毒疾病中TREM2在脑和生物体液中的表达, objectType=article, longId=211431, objectId=e71a21143137, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e71a21143137, replyNumber=0, likeNumber=84, createdTime=2021-12-18, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e71a21143137, moduleTitle=Acta Neuropathologica: 朊病毒疾病中TREM2在脑和生物体液中的表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e71a21143137)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796390, encodeId=81fb1e96390b4, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Acta Neuropathologica: 在MS模型中，小胶质细胞上的TREM2激活促进髓鞘碎片清除和髓鞘再形成, objectType=article, longId=200990, objectId=425520099070, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=425520099070, replyNumber=0, likeNumber=118, createdTime=2021-06-29, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=425520099070, moduleTitle=Acta Neuropathologica: 在MS模型中，小胶质细胞上的TREM2激活促进髓鞘碎片清除和髓鞘再形成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=425520099070)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796392, encodeId=45451e96392dd, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=TREMFYA（guselkumab）治疗活动性银屑病关节炎（PsA）：已获得CHMP的积极意见, objectType=article, longId=202280, objectId=18ae2022800c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ae2022800c, replyNumber=0, likeNumber=82, createdTime=2020-11-21, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ae2022800c, moduleTitle=TREMFYA（guselkumab）治疗活动性银屑病关节炎（PsA）：已获得CHMP的积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18ae2022800c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796395, encodeId=69ed1e96395d7, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Clin Cancer Res：Durvalumab+Tremelimumab+放疗用于错配修复正常的转移性结直肠癌的疗效, objectType=article, longId=206790, objectId=0006206e9068, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0006206e9068, replyNumber=0, likeNumber=87, createdTime=2021-09-07, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0006206e9068, moduleTitle=Clin Cancer Res：Durvalumab+Tremelimumab+放疗用于错配修复正常的转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0006206e9068)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796388, encodeId=b2ee1e96388c0, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=CELL：TREM2可增强肿瘤抗PD-1免疫治疗效果 , objectType=article, longId=199294, objectId=7bfe199294c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bfe199294c1, replyNumber=0, likeNumber=129, createdTime=2021-01-09, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bfe199294c1, moduleTitle=CELL：TREM2可增强肿瘤抗PD-1免疫治疗效果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bfe199294c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796384, encodeId=663e1e9638423, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=durvalumab联合tremelimumab治疗膀胱癌：无法改善OS, objectType=article, longId=189553, objectId=2c1918955355, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c1918955355, replyNumber=0, likeNumber=134, createdTime=2020-12-04, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c1918955355, moduleTitle=durvalumab联合tremelimumab治疗膀胱癌：无法改善OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c1918955355)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796385, encodeId=3efa1e963852c, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！, objectType=article, longId=192695, objectId=249d19269580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=249d19269580, replyNumber=0, likeNumber=67, createdTime=2020-10-28, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=249d19269580, moduleTitle=斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=249d19269580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796386, encodeId=83d31e96386f6, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）, objectType=article, longId=197593, objectId=979d19e59394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=979d19e59394, replyNumber=0, likeNumber=110, createdTime=2020-11-04, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=979d19e59394, moduleTitle=FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=979d19e59394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796387, encodeId=87ca1e96387f2, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Cell：髓系细胞免疫信号枢纽——TREM2, objectType=article, longId=198086, objectId=766f198086b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=766f198086b5, replyNumber=0, likeNumber=127, createdTime=2020-09-25, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=766f198086b5, moduleTitle=Cell：髓系细胞免疫信号枢纽——TREM2, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=766f198086b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796389, encodeId=ea6c1e96389bf, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=令人惊喜！Cell：阻断TREM2可增强肿瘤免疫疗法，小鼠模型肿瘤完全清除, objectType=article, longId=199451, objectId=a0b619945110, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0b619945110, replyNumber=0, likeNumber=88, createdTime=2021-02-27, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0b619945110, moduleTitle=令人惊喜！Cell：阻断TREM2可增强肿瘤免疫疗法，小鼠模型肿瘤完全清除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0b619945110)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TREM

2020-05-29

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者

2022-05-05

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

NEJM Evid：Tremelimumab联合Durvalumab用于不可切除肝细胞癌的治疗

2022-11-04

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率

2022-09-16

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Lancet Neurol：可溶性TREM2与常染色体显性遗传阿尔茨海默病其他标志物及认知功能的相关性

2022-06-28

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处

2022-12-02

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性

2022-04-11

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究

2021-09-27

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

欧盟委员会批准了TREMFYA®（guselkumab）治疗活动性银屑病关节炎（PsA）

2021-03-23

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

TREMFYA（guselkumab）治疗成人银屑病关节炎：显著减少了疲劳症状

2021-07-28

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率

2021-01-04

智者为医08 (审核中...)

前往app查看评论内容

#TREM#

Acta Neuropathologica: 朊病毒疾病中TREM2在脑和生物体液中的表达

2021-12-18

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Acta Neuropathologica: 在MS模型中，小胶质细胞上的TREM2激活促进髓鞘碎片清除和髓鞘再形成

2021-06-29

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

TREMFYA（guselkumab）治疗活动性银屑病关节炎（PsA）：已获得CHMP的积极意见

2020-11-21

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Clin Cancer Res：Durvalumab+Tremelimumab+放疗用于错配修复正常的转移性结直肠癌的疗效

2021-09-07

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

CELL：TREM2可增强肿瘤抗PD-1免疫治疗效果

2021-01-09

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

durvalumab联合tremelimumab治疗膀胱癌：无法改善OS

2020-12-04

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！

2020-10-28

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）

2020-11-04

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Cell：髓系细胞免疫信号枢纽——TREM2

2020-09-25

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

令人惊喜！Cell：阻断TREM2可增强肿瘤免疫疗法，小鼠模型肿瘤完全清除

2021-02-27

科室
- - 订阅+
  - 更多科室
工具
服务